Responses
Clinical and epidemiological research
Concise report
Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial
Compose a Response to This Article
Other responses
No responses have been published for this article.